- Home
- CDRE vs PCRX Comparison
CDRE vs PCRX Comparison
Compare CDRE & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- PCRX
- Stock Information
- Founded
- CDRE 2012
- PCRX 2006
- Country
- CDRE United States
- PCRX United States
- Employees
- CDRE N/A
- PCRX N/A
- Industry
- CDRE Industrial Specialties
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CDRE Health Care
- PCRX Health Care
- Exchange
- CDRE Nasdaq
- PCRX Nasdaq
- Market Cap
- CDRE 1.2B
- PCRX 1.2B
- IPO Year
- CDRE 2021
- PCRX 2011
- Fundamental
- Price
- CDRE $32.87
- PCRX $24.10
- Analyst Decision
- CDRE Buy
- PCRX Buy
- Analyst Count
- CDRE 2
- PCRX 9
- Target Price
- CDRE $37.50
- PCRX $29.89
- AVG Volume (30 Days)
- CDRE 300.8K
- PCRX 546.7K
- Earning Date
- CDRE 08-08-2025
- PCRX 07-29-2025
- Dividend Yield
- CDRE 1.15%
- PCRX N/A
- EPS Growth
- CDRE N/A
- PCRX N/A
- EPS
- CDRE 0.95
- PCRX N/A
- Revenue
- CDRE $559,807,000.00
- PCRX $702,772,000.00
- Revenue This Year
- CDRE $13.31
- PCRX $7.54
- Revenue Next Year
- CDRE $7.96
- PCRX $10.78
- P/E Ratio
- CDRE $35.63
- PCRX N/A
- Revenue Growth
- CDRE 10.06
- PCRX 3.08
- 52 Week Low
- CDRE $27.07
- PCRX $11.16
- 52 Week High
- CDRE $40.28
- PCRX $29.61
- Technical
- Relative Strength Index (RSI)
- CDRE 43.22
- PCRX 36.99
- Support Level
- CDRE $33.85
- PCRX $23.99
- Resistance Level
- CDRE $36.43
- PCRX $24.90
- Average True Range (ATR)
- CDRE 0.92
- PCRX 0.88
- MACD
- CDRE -0.22
- PCRX -0.21
- Stochastic Oscillator
- CDRE 12.97
- PCRX 11.61
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.